They seem to have done the right things. Streamlined and focused on their main areas of opportunity. Ab business looks set to grow too. They now seem much better designed to succeed, I am hopeful (and not an employee)
What they are is a joke. Their revenue is not going to crack $15MM anymore, yet they are public, thus wasting an incredible amount of money on regulatory affairs, investor relations, filings., etc. Their GAT technology works only a small percentage of the time, their so called catalog is never mentioned anymore despite the PR regarding NovusBio. Where is all this work coming from? BD terminated their agreement, and here we are nearign April and no earnings report. Maybe they can do Q1 and 2012 in the same call. And they are well past their "month late" timing we were waiting for.